NICE may recommend Erbitux in metastatic colorectal cancer after all
This article was originally published in Scrip
Colorectal cancer patients in the national health service in England and Wales may be given access to Merck Serono's (Merck KGaA) Erbitux (cetuximab) in narrow circumstances, new draft guidance from the National Institute for health and Clinical Excellence (NICE) suggests.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.